Leading Industry Experts to Present at Lonza’s 2nd Global Endotoxin Testing Summit
News Mar 01, 2016
Returning to the line-up is Lonza Senior Scientist Kevin Williams. With more than 30 years of hands-on experience in the area of pharmaceutical quality control, Williams is a recognized expert in the field of endotoxin detection. In addition, Johannes Reich of Hyglos GmbH will return to the event to provide an update on his theory behind the underlying mechanism of Low Endotoxin Recovery (LER).
Lakiya Wimbish, Lonza Product Manager Endotoxin Detection, commented, “With these two speakers and other world-class industry thought leaders attending and presenting at the 2nd Global Endotoxin Testing Summit, the event will provide an opportunity for QC Directors, lab managers, key opinion leaders, users and regulators to discuss current issues within the endotoxin detection industry and to make progress in improving pharmaceutical safety.”
The 2nd Global Endotoxin Testing Summit agenda will address industry hot topics ranging from endotoxin testing basics to regulatory guidance updates and Low Endotoxin Recovery. The summit will also cover the use and relevance of naturally occurring endotoxin (NOE) in hold-time studies, explore new opportunities for process optimization and discuss ways to address variability associated with the kinetic chromogenic assay.
Fermentation Byproduct Suppresses Seizures in Nerve Agent PoisoningNews
A compound found in trace amounts in alcoholic beverages is more effective at combating seizures in rats exposed to an organophosphate nerve agent than the current recommended treatment.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018